Form 4: PTC Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CEO Eric Pauwels sold shares of PTC Therapeutics stock to cover tax obligations arising from the vesting of restricted stock units (RSUs).
Summary
- Eric Pauwels, the CEO of PTC Therapeutics, sold shares of common stock on February 19, 2025, and February 20, 2025.
- The sales were executed to cover tax withholding obligations related to the vesting of RSUs.
- On February 19, 2025, 1,378 shares were sold at a price of $50.096 per share.
- On February 20, 2025, 1,567 shares were sold at a price of $50.124 per share.
- Following these transactions, Pauwels directly owns 83,860 shares of PTC Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of share sales to cover tax obligations, which is neither particularly positive nor negative.
Industry Context
Sales of shares to cover tax obligations upon vesting of RSUs are a common practice among executives of publicly traded companies.
Stakeholder Impact
- The share sales have a minimal impact on shareholders as they are related to tax obligations and do not indicate a change in the CEO's long-term outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 02/15/2024 | Date of RSU grants (22,000 RSUs and 2,300 RSUs) that led to the tax obligations. |
| 02/19/2025 | Date of first share sale (1,378 shares). |
| 02/20/2025 | Date of second share sale (1,567 shares). |
| 02/21/2025 | Date of Form 4 filing. |
Keywords
PTC Therapeutics, Eric Pauwels, Form 4, Share Sale, RSU Vesting, Tax Obligations, PTCT, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.